This study was designed to assess the comparative efficacy of normal saline (NS) and 5% albumin (ALB) for treatment of hypotension in the acutely ill newborn.
BACKGROUND
Hypotension in both preterm and term infants is a common problem in the immediate neonatal period. Maintenance of circulating blood volume, cardiac function, and vasomotor tone is necessary for stabilization of arterial blood pressure. Treatment typically begins with the expansion of intravascular blood volume with either crystalloid or colloid (whole blood, albumin, or plasma) solutions. There has been considerable debate in the adult medical literature regarding which solution is more effective, 1-7 yet little is found pertaining to preterm and term newborns. The core of the controversy in the adult literature involves the potential development of pulmonary edema associated with crystalloid infusion. 1, 2 Proponents who favor the use of colloid solutions for volume expansion note the importance of maintaining colloid oncotic pressure to prevent tissue extravasation of exogenously administered fluids. 1, 2, 4 However, randomized trials in the adult population comparing Ringer's lactate to albumin (ALB) demonstrated no significant difference in the development of pulmonary edema between study groups. Crystalloid solution was as efficacious as colloid solution for expansion of intravascular volume. [5] [6] [7] In the sick premature infant, ALB infusion has been shown to be beneficial for increasing blood volume, increasing arterial blood pressure, and improving renal function. 8 Comparison of various concentrations of colloid solutions utilized in the treatment of hypotensive preterm infants demonstrated that total volume infused is more important in sustaining blood pressure than actual protein load. 9 More recently, investigators from Hong Kong found normal saline (NS) to be as effective as ALB in treating hypotensive preterm infants with respiratory distress syndrome. These investigators also observed that NS caused less fluid retention than ALB. 10 Based on these findings, we hypothesized that NS would be as efficacious as ALB in sustaining an increase in MAP in the preterm and term infant.
PATIENTS AND METHODS
Infants admitted to the Holden Neonatal Intensive Care Unit at the University of Michigan, who developed acute hypotension within the first 24 hours of life, were eligible for the study. Patients were enrolled between December 1997 and January 1999. The study was approved by the Institutional Review Board and written informed consent was obtained from a parent prior to enrollment in the study. Infants were stratified by birthweight into one of two groups prior to randomization: <2500 and Z2500 g. Hypotension was defined as a mean arterial pressure (MAP) below the 95th percentile confidence interval for each stratified birthweight as extrapolated from linear regression lines of mean systolic and diastolic blood pressures as defined by Zubrow et al. 11 This corresponded to a MAP of <30 mmHg for infants <2500 g and <40 mmHg for infants Z2500 g. Infants were randomized to receive volume expansion in the form of either NS or ALB. Randomization was accomplished by random number tables via sealed, serially numbered envelopes. Mean arterial blood pressure was measured by an automated oscillometric device. The device was placed over the right upper extremity according to a standard nursing protocol. The inflatable portion of the cuff encircled 75% or more of the limb circumference and the length of the cuff had to be at least two-thirds of the length of the upper limb segment. If an infant was too small for a measurement in the right upper extremity, the right lower extremity was used following a similar protocol.
The study included infants less than 24 hours old who presented with hypotension. Exclusion criteria included anemia (hematocrit <40%), culture-proven sepsis, congenital heart disease, lifethreatening congenital anomalies, hydrops fetalis, known renal disease, insulin-requiring maternal diabetes mellitus, unresolved air leak, and/or treatment with high-frequency oscillatory ventilation (HFOV). Baseline vital signs including temperature, heart rate, respiratory rate, systolic and diastolic blood pressures, MAP, and urine output were recorded prior to treatment. Ventilator settings and arterial blood gas measurements were also recorded prior to infusion. A baseline central hematocrit was obtained. If the infant had a hematocrit value less than 40%, a packed red cell infusion was administered initially.
Following randomization, infants were given a 10 ml/kg infusion of the assigned solution over 15 minutes. This infusion could be repeated a second time if the infant failed to respond initially. Vital signs were recorded every 15 minutes throughout the infusion. Success was defined as at least 30 minutes of sustained MAP above the hypotensive criterion after volume therapy. If the infant remained hypotensive after the second infusion, volume expansion was considered inadequate and pressor support was initiated.
Post-treatment vital signs were recorded. All data were documented on a standardized collection form designed specifically for this study. Statistical comparisons were made using analysis of variance (ANOVA) for continuous variables and w 2 analysis or Fisher's exact test for categorical variables. A 20% difference between the two treatment groups in the correction of hypotension was deemed clinically significant as determined by the Students's t-test. A sample size calculation demonstrated the need for 20 patients in each group in order to achieve a power of 80% (p<0.05). The calculation was based on an acceptable MAP and a standard deviation of 10 mmHg as estimated from Zubrow et al. 11 
RESULTS
In total, 50 infants were enrolled in the study and were randomly assigned to receive either ALB or NS. Nine infants <2500 g were subsequently excluded, including five who required high-frequency ventilation prior to completion of treatment, and four who had uncorrected hematocrit values <40%. They were evenly distributed between the two treatment groups. Of the remaining 41 infants, 21 received ALB and 20 received NS. There were no significant differences between groups for gender, gestational age, birthweight, or baseline hematocrit (Table 1 ). There was one death among infants in the NS group, and four deaths among infants in the ALB group. None of these deaths was related to treatment for hypotension.
The mean increases for MAP values in each of the treatment groups pre-and post-treatment were compared. Multiple comparisions between treatment groups were performed using two-way analysis of variance (ANOVA). There was no statistically significant difference between groups with respect to pretreatment MAP (p ¼ 0.296), post-treatment MAP (p ¼ 0.321), or percent increase in MAP (p ¼ 0.169) when comparing treatment groups with birthweight. Seven of the 20 infants in the NS group (35%) required a second volume infusion, and three of these patients required further inotropic support. Nine of the 21 infants (43%) in the ALB group required a second volume infusion, and four of these 21 patients required inotropic support for treatment failure. There was no statistically significant difference in need for a second infusion (p ¼ 0.444) or treatment failure rates (p ¼ 0.697) between the groups.
There was no statistically significant difference in the number of infants who responded to treatment successfully between the groups (p ¼ 0.69, Fisher's exact test). No difference was seen in the incidence in germinal matrix hemorrhage-intraventricular hemorrhage (GMH-IVH) between the treatment groups ( Table 2) . There was no significant change in either baseline heart rate or respiratory rate after treatment in either group.
DISCUSSION
In this randomized study, NS was as effective as ALB for the treatment of acute hypotension in newborn infants. No statistically significant differences were detected between the two solutions for increasing and sustaining MAP for 30 minutes postinfusion. Both solutions were effective in increasing MAP for both large and small infants in each group. There were no significant differences between groups in either the need for a second volume infusion, or subsequent need for inotropic support. The five deaths observed in this trial were among extremely low-birth-weight infants (<800 g), all of whom succumbed to complications arising from necrotizing enterocolitis. The ALB group had a higher percentage of deaths (19%) compared to the NS group (5%), but it did not reach statistical significance. This trend is consistent with a previously published meta-analysis of other randomized, controlled trials comparing use of colloid to crystalloid solutions for volume resuscitation. 12 This finding could also represent a selection bias of sicker patients being randomly assigned to the ALB group. However, the number of patients in this present trial is too small to infer conclusions about treatment-associated mortality/morbidity, and further study is recommended. Other limitations to this study include its unblinded design, exclusion of nine patients following randomization and treatment, and lack of reported long-term outcomes. The inability to blind the study certainly lends to possible bias, as the physical appearance of ALB made those infants receiving it easily identifiable. However, strict protocol guidelines were followed and the treatment period was kept short. The protocol was designed to begin and end within the first 24 hours of life, therefore randomization occurred shortly after birth to allow immediate treatment if hypotensive criteria were met. Four infants were randomized and treated before the baseline hematocrits were known. Five infants required HFOV due to rapidly deteriorating respiratory status during the treatment protocol. Owing to concerns with high mean airway pressure impeding cardiac output, these infants could not be included. The study was not designed to report long-term outcomes (other than death) or safety comparisons but rather immediate, short-term effects of treatment. Further studies to evaluate long-term outcomes are warranted.
Enrollment criteria were strictly enforced to avoid introduction of confounding variables. This study was used to compare NS to ALB in terms of their respective abilities to treat hypotension solely through expansion of intravascular volume. Any clinical condition in which cardiac output was compromised (e.g. sepsis, heart disease, pneumothorax, HFOV with high mean airway pressures) was cause for exclusion from the study. This provided a more homogenous study population, but it may have kept sicker patients from being included in the comparison. Future studies might compare the use of these two solutions for treatment of hypotension in infants with specific illnesses which impair cardiac output.
Finally, crystalloid solutions are far less costly than colloid solutions. Recent review of inpatient costs at the University of Michigan Health System found that 20 ml of NS cost $1.50, and 20 ml of ALB cost $33.40. 13 Colloid solution also carries a small risk of hazardous infection transmission as a biological product derived from pooled human donors.
The results of our randomized study show that NS is as effective as ALB for the treatment of hypotension in critically ill newborn infants. It is safe, considerably less expensive, and readily available. NS should be considered the initial treatment of choice in this setting.
